Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 80 years old (inclusive), of any gender
• People who have a confirmed diagnosis of Mantle Cell Lymphoma (MCL), based on laboratory testing of tissue or cell samples, with at least one area of disease that can be measured on scans
• People who have not previously received any systemic (whole-body) treatment for MCL
• People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (ECOG score of 0 to 2 — confirm with trial site if unsure what this means)
• People whose blood cell counts are within acceptable levels without having needed a blood transfusion, growth factor support, or corrective medication in the 14 days before joining
• People whose liver and kidney function test results fall within acceptable ranges, as defined by the trial
• People whose heart is pumping at an adequate level, confirmed by an echocardiogram (heart ultrasound)
• Women who could become pregnant must have a negative pregnancy blood test within 7 days before starting the trial, and must agree to use a highly effective form of contraception during the trial and for 6 months after the last dose
• Men whose partners could become pregnant must either have had a surgical sterilisation procedure or agree to use effective contraception during the trial and for 6 months after the last dose
• People who are willing and able to sign a consent form and attend required follow-up appointments

Who may not be able to join:

• People whose lymphoma has spread to the brain or the lining around the brain or spinal cord
• People with severe heart failure (classified as NYHA Class III or IV — confirm with trial site)
• People who have had another type of cancer in the past 3 years, with some exceptions such as certain skin cancers, localised prostate cancer considered cured, or certain early-stage cervical conditions
• People who have previously been treated with an experimental or investigational drug
• People who have an active serious infection (viral, bacterial, or fungal) that requires antibiotic or antifungal treatment within 2 weeks before starting the trial
• People who have taken immune-suppressing medications within 7 days before starting the trial, with some exceptions for low-dose inhaled or nasal steroids or low-dose oral steroids
• People who have had a severe allergic reaction to a monoclonal antibody (a type of targeted treatment), or who have a known allergy or intolerance to intravenous infusions, or who have had a severe allergy to any of the study drugs or pre-medications
• People with known immune system deficiencies, including active hepatitis B, hepatitis C, or HIV/AIDS
• People who are pregnant or breastfeeding, or people who could become pregnant but are unwilling or unable to use effective contraception
• People with any other condition that the trial doctor believes could affect their safety or their ability to follow the trial requirements

Important: Always verify eligibility with the trial site directly before applying.